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Background: Pyoderma gangrenosum is an inflammatory neutrophilic dermatosis characterized by painful
cutaneous ulcerations and often associated with systemic inflammatory and neoplastic diseases. Here we report the
first case of pyoderma gangrenosum in a patient with refractory celiac disease.
Case presentation: A 52-year-old woman with a previously diagnosed refractory celiac disease resistant to steroids
and immunosuppressive drugs presented to our hospital for a rapidly growing, painful inflammatory skin lesion of
the left leg. Physical examination revealed a painful lesion with focal ulceration, necrosis and pus discharge with
active inflammatory borders at the external part of the left leg. Histological evaluation of a skin biopsy and analysis
of inflammatory cytokines and matrix-degrading proteases in lesional skin samples confirmed the clinical suspicion
of pyoderma gangrenosum. Treatment with oral prednisone was rapidly followed by a complete healing of the skin
lesion but no improvement of symptoms/signs of malabsorption.
Conclusion: Treatment of the patient with systemic steroids healed the skin lesion without improving the
underlying refractory celiac disease. This observation raises the possibility that refractory celiac disease and
pyoderma gangrenosum may be immunologically different.
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Pyoderma gangrenosum (PG) is an inflammatory neutro-
philic dermatosis characterized by painful cutaneous ul-
cerations persisting for more than 4 weeks [1]. Although
accurate epidemiological data on PG are missing, the gen-
eral incidence has been estimated to be between 3 and 10
per million per year, with a peak of incidence between the
ages of 20 to 50 years [2-6]. Women are affected more fre-
quently than men. Based on clinical presentation, PG can
be differentiated in four major types: ulcerative, pustular,
bullous and vegetative [3-5]. The diagnosis of PG requires
the exclusion of other disorders, which can manifest with
cutaneous ulceration (e.g. infections, vascular diseases,
malignancies), and is based on clinical history, histopatho-
logical findings and response to therapy. Histopathological
analysis of skin biopsies is useful to exclude other patholo-
gies which clinically mimic PG rather than establishing a* Correspondence: Gi.Monteleone@Med.uniroma2.it
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reproduction in any medium, provided the ordiagnosis of PG per se [3,4,7]. PG occurs most commonly
on the lower legs with preference for the pretibial area or
on peristomal areas. Other sites of involvement include
breast, hand, trunk, head and neck. Moreover PG can
have extracutaneous manifestations, such as involvement
of upper airway mucosa, genital mucosa and eye, spleen
infiltrates, neutrophilic myositis, sterile pulmonary neutro-
philic infiltrates and sterile cortical osteolysis. It has been
however suggested that the diagnosis of PG should be
questioned when the legs or peristomal areas are not in-
volved [3-5,7].
Although PG can manifest in individuals apparently
healthy, it is frequently associated with inflammatory or
neoplastic systemic diseases, such as inflammatory bowel
diseases, rheumatic disorders, leukemia and myelodys-
plastic syndrome [3-5]. Furthermore, an association with
such diseases in the context of skin ulcerations with
crater-like holes and cribiform scarring helps make the
final diagnosis of PG [3-5], thus highlighting the diag-
nostic relevance of identifying diseases which might be
associated to PG.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Ulcerative necrotic lesion on the anterior face of
left leg.
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http://www.biomedcentral.com/1471-230X/13/162Here we describe a case of PG complicating the nat-
ural history of a woman with refractory celiac disease
(RCD), a form of celiac disease (CD) characterized by
symptoms/signs of malabsorption and villous atrophy
unresponsive to a strict gluten-free diet (GFD) [8].
Case presentation
A 52-year-old woman presented at the Gastroenterology
Unit, University Tor Vergata Hospital, (Rome, Italy) in
April 2011. Since 1990, the patient was complaining of
diarrhea, abdominal pain and weight loss. In March
1993, CD was diagnosed based on positive serologic tests
[anti-endomysium IgA antibody (EMA), anti-tissue
transglutaminase-2 (TG-2) antibody], evidence of total
villous atrophy of duodenal biopsies taken during upper
gastrointestinal endoscopy, and positivity for human
leukocyte antigen-DQ2. In October 2005, for the persist-
ence of malabsorption symptoms/signs, despite a strict
adherence to a GFD since 1993, the patient underwent
further endoscopic and laboratory investigations, and
eventually RCD was diagnosed. Therefore, she was
treated with several courses of steroids and cyclosporine
A with partial clinical response. Upon admission, she
complained of abdominal pain, diarrhea (5 stools/day)
and asthenia, despite she was on a strict GFD and
treated with prednisolone (0.4 mg/kg/day). Her body
mass index (BMI) was 15,6 kg/m2; the remaining phys-
ical examination was unremarkable. Laboratory analysis
revealed exclusively anemia. Thyroid gland function tests
were normal. EMA, anti-TG-2 and anti-enterocyte anti-
bodies were negative. A bone density scan revealed low
bone mineral density. Diagnostic work-up for infectious
agents was negative. Colonoscopy with histological
evaluation of colonic biopsies, CT enterography andFigure 1 Photomicrographs of HE-stained paraffin section of a
duodenal mucosal biopsy sample taken from a patient with
refractory celiac disease showing subtotal villous atrophy and
increased inflammatory cell infiltrates of the lamina propria
compartment (original magnification 100x).small intestine contrast ultrasonography were normal.
An upper endoscopy was performed and histological
evaluation of duodenal biopsies showed an increased infil-
tration of the epithelial compartment with lymphocytes,
crypts hyperplasia and a subtotal villous atrophy (Marsh
3b stage) (Figure 1). Further histological assessment of
duodenal samples showed no collagen deposition. Diag-
nostic work-up for other villous atrophy-induced diseases
(e.g. NSAIDs, olmesartan use, collagenous sprue and com-
mon variable immunodeficiency) was negative. Immuno-
phenotyping analysis showed the absence of aberrant
intraepithelial lymphocytes (RCD type I). Since a new
course of steroids (prednisone 0.5 mg/kg/day) was unsuc-
cessful and the patient refused to be treated with azathio-
prine, anti-TNF-α antibody infusion was scheduled for
November 2011. However, in October 2011, she wasTable 1 Cytokine and MMP transcripts in lesional and
non-lesional skin of one refractory celiac disease patient
RNA transcript relative expression
IL-8 IL-17A MMP-2 MMP-9
Non-Lesional skin 1 1.2 1.1 1.1
Lesional skin 10.1 8.2 9 92.3
Total RNA was extracted using Pure Link mRNA mini kit according to the
manufacturer’s instructions (Life Technologies, Milan, Italy). A constant amount
of RNA (1 μg/sample) was retro-transcribed into complementary DNA (cDNA)
and then 1 μl of cDNA/sample was amplified using the following conditions:
denaturation 1 minute at 95°C; annealing 30 seconds at 55°C for MMP-2, at
58°C for IL-8 and MMP-9, at 61° for IL-17A and at 60°C for β-Actin, followed by
30 seconds of extension at 72°C. Primers’ sequences were as follows: IL-8 for-
ward 5′-AGGAACCATCTCACTGTGTG-3′, reverse 5′-CCACTCTCAATCACTCTCAG-3′;
IL-17A forward 5′-ACTACAACCGATCCACCTCAC-3′, reverse 5′-ACTTTGCCTCCCA-
GATCACAG-3′; MMP-2 forward 5′-TGACGGAAAGATGTGGTGTG-3′, reverse 5′-
GGTGTAGGTGTAAATGGGTG-3′; MMP-9 forward 5′-CGTCTTCCAGTACCGAGAGA-
3′, reverse 5′-GCAGGATGTCATAGGTCACG-3′; β-actin forward 5′-AAGATGACCCA-
GATCATGTTTGAGACC-3′, reverse 5′-AGCCAGTCCAGACGCAGGAT-3′ was used as
internal control gene. RNA expression was calculated relative to the house-
keeping β -actin gene on the base of the ΔΔCt algorithm.
Abbreviations: IL, interleukin, MMP, matrix metalloproteinase.
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ful inflammatory skin lesion of the left leg. At that time
she was treated with oral prednisone (0.2 mg/kg/day) and
complaining of diarrhea and abdominal pain. Physical
examination revealed a painful lesion with focal ulceration,
necrosis and pus discharge with active inflammatory bor-
ders at the external part of the left leg (Figure 2). Histo-
logical evaluation of a skin biopsy taken 7 days later in the
Dermatology clinic at the Tor Vergata University Hospital,
Rome, showed an irregular acantotic epidermis and under-
lying scarring dermis with acute and chronic inflammatory
cell infiltrates. Additional biopsy samples were collected
from both lesional and non-lesional skin and used to as-
sess RNA expression of interleukin (IL)-8, IL-17A, matrix
metalloproteinase (MMP)-2 and MMP-9, because these
molecules are involved in the recruitment of neutrophils
to the skin and supposed to play a key role in the patho-
genesis of PG [9,10]. RNA transcripts of IL-17A, IL-8,
MMP-2 and MMP-9 were more pronounced in the af-
fected skin as compared to non-lesional skin (Table 1). PG
was eventually diagnosed and patient was treated with oral
prednisone (0.7 mg/kg/day). A dramatic improvement was
observed; the pain diminished considerably and a
complete healing of the skin lesion was documented in
December 2011. No recurrence was observed after a
follow-up period of 8 months.
Conclusions
CD is an immune-mediated enteropathy triggered by the
ingestion of gluten in genetically-susceptible individuals
[11]. The clinical spectrum of CD is wide, ranging from
asymptomatic presentations to symptomatic cases with
either classical intestinal (e.g. abdominal pain, chronic diar-
rhea, weight loss) or non-classical extraintestinal (e.g.
anemia, osteoporosis) features [11]. CD can be associated
with cutaneous manifestations, which can improve follow-
ing exclusion of gluten from the diet. The most common
CD-associated skin pathologies are dermatitis herpetifor-
mis, which is characterized by itchy, chronic, papulo-
vesicular eruption, and psoriasis [12].
This is the first case to show a possible association be-
tween RCD and PG. Interestingly, PG responded rapidly
to steroids while no simultaneous improvement of the
underlying RCD was seen. This raises the possibility that
RCD and PG are immunologically different disorders.
We feel it is fair to conclude that physicians should con-
sider this putative association so that appropriate med-
ical therapy can be started early on.
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